Table 1. Characteristics of patients and analysis of ipsilateral recurrence.
| Total | Ipsilateral recurrences (5-year cumulative incidence %) | P-value | |
|---|---|---|---|
|
All patients |
1171 |
163 (10.7) |
|
|
Age (years) | |||
| ⩽39 | 61 (5.2) | 20 (28.5) | <0.01 |
| 40–49 | 431 (36.8) | 65 (12.3) | |
| 50–64 | 479 (40.9) | 57 (8.0) | |
| ⩾65 |
200 (17.1) |
21 (8.4) |
|
|
Menopause | |||
| Pre | 549 (46.9) | 93 (13.3) | <0.01 |
| Post |
622 (53.1) |
70 (8.4) |
|
|
BMIa
(kg m–2) | |||
| <18.5 | 51 (4.6) | 9 (16.8) | 0.30 |
| 18.5–24.9 | 743 (66.4) | 110 (10.6) | |
| 25–29.9 | 244 (21.8) | 26 (8.9) | |
| ⩾30 |
81 (7.2) |
10 (12.9) |
|
|
Main histotype | |||
| Comedo | 91 (7.8) | 15 (15.2) | 0.25 |
| Solid | 451 (38.5) | 57 (8.4) | |
| Micropapillar | 162 (13.8) | 29 (14.5) | |
| Cribriform | 430 (36.7) | 57 (10.7) | |
| Hypersecretory | 5 (0.4) | 2 (40.0) | |
| Apocrine |
32 (2.7) |
3 (6.4) |
|
|
Distance from tumour to surgical margins (mm) | |||
| >0 and <1 | 148 (12.7) | 20 (10.5) | 0.17 |
| ⩾1 and <10 | 141 (12.0) | 27 (16.1) | |
| ⩾10 |
882 (75.3) |
116 (9.8) |
|
|
Microcalcificationsa | |||
| Absent | 290 (24.9) | 56 (16.2) | <0.01 |
| Present |
875 (75.1) |
107 (9.0) |
|
|
Necrosisa | |||
| Absent | 485 (41.5) | 82 (13.4) | 0.02 |
| Present |
683 (58.5) |
81 (8.9) |
|
|
Grade | |||
| DIN1 | 224 (19.1) | 28 (9.1) | 0.66 |
| DIN2 | 619 (52.9) | 90 (10.4) | |
| DIN3 |
328 (28.0) |
45 (12.4) |
|
|
ER (%) | |||
| 0 | 230 (19.6) | 25 (9.8) | 0.28 |
| 1–49 | 89 (7.6) | 17 (14.7) | |
| 50–100 |
852 (72.8) |
121 (10.5) |
|
|
PgR (%) | |||
| 0 | 360 (30.7) | 43 (9.7) | 0.39 |
| 1–49 | 348 (29.7) | 52 (11.9) | |
| 50–100 |
463 (39.5) |
68 (10.5) |
|
|
Ki-67 LI (%) | |||
| <14 | 538 (45.9) | 66 (9.4) | 0.05 |
| 14–20 | 272 (23.2) | 39 (10.3) | |
| >20 |
361 (30.8) |
58 (13.0) |
|
|
HER2/neu overexpression | |||
| Absent | 773 (66.0) | 105 (9.6) | 0.67 |
| Present |
398 (34.0) |
58 (12.9) |
|
|
Molecular subtype | |||
| Luminal A | 463 (39.5) | 56 (9.1) | 0.20 |
| Luminal B (HER2neg) | 267 (22.8) | 44 (10.3) | |
| Luminal B (HER2pos) | 213 (18.2) | 38 (15.3) | |
| HER2 | 185 (15.8) | 20 (10.0) | |
| Triple negative |
43 (3.7) |
5 (9.8) |
|
|
Surgery | |||
| BCS | 872 (74.5) | 142 (12.4) | <0.01 |
| Mastectomy |
299 (25.5) |
21 (5.6) |
|
|
Hormonal treatment ERpos only | |||
| Yes | 506 (53.7) | 62 (9.8) | 0.05 |
| No |
435 (46.3) |
76 (12.2) |
|
|
Radiotherapy BCS only | |||
| Yes |
356 (40.8) |
37 (8.5) |
<0.01 |
| No | 516 (59.2) | 105 (15.1) | |
Abbreviations: BCS=breast-conserving surgery; BMI=body mass index; DIN=ductal intraepithelial neoplasia; ER=oestrogen receptor; ERpos= ER positive; HER2=human epidermal growth factor receptor-2; LI=labelling index; PgR=progesterone receptor.
a
Some patients had missing data. Ipsilateral recurrences: local in situ, local invasive and loco-regional invasive.